| New Hope Counseling Services Llc | |
|
609 N Hepburn Ave Ste 103 Jupiter FL 33458-5015 | |
| (561) 628-2352 | |
| Not Available |
| Full Name | New Hope Counseling Services Llc |
|---|---|
| Speciality | Social Worker |
| Location | 609 N Hepburn Ave, Jupiter, Florida |
| Authorized Official Name and Position | Natalie Lendak (OWNER) |
| Authorized Official Contact | 5616282352 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| New Hope Counseling Services Llc 609 N Hepburn Ave Ste 103 Jupiter FL 33458-5015 Ph: () - | New Hope Counseling Services Llc 609 N Hepburn Ave Ste 103 Jupiter FL 33458-5015 Ph: (561) 628-2352 |
| NPI Number | 1154678688 |
|---|---|
| Provider Enumeration Date | 08/15/2012 |
| Last Update Date | 09/07/2012 |
| Medicare PECOS PAC ID | 7618125816 |
|---|---|
| Medicare Enrollment ID | O20120913000076 |
News Archive
A new treatment strategy using targeted nanoparticles to block metastasis with anti-cancer drugs leads to good results using significantly lower doses of toxic chemotherapy, with less collateral damage to surrounding tissue, according to a collaborative team of researchers at the Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer at the University of California, San Diego. In designing this system, the investigators, led by David Cheresh, Ph.D., have identified what may become a generic method for using nanotechnology to target metastasis.
Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.
A new Canadian study suggests that individuals who take anti-depressants and/or anti-psychotics and participate in a weight management program can lose weight whether or not they take psychiatric medications, according to a report published online today in Obesity, the flagship journal of The Obesity Society.
Australian researchers have begun a world-first study that aims to help men lose weight and prevent diabetes - by giving them more testosterone.
GlaxoSmithKline has issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154678688 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
| Provider Name | Natalie A Lendak |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1376782649 PECOS PAC ID: 1850549056 Enrollment ID: I20120928000127 |
News Archive
A new treatment strategy using targeted nanoparticles to block metastasis with anti-cancer drugs leads to good results using significantly lower doses of toxic chemotherapy, with less collateral damage to surrounding tissue, according to a collaborative team of researchers at the Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer at the University of California, San Diego. In designing this system, the investigators, led by David Cheresh, Ph.D., have identified what may become a generic method for using nanotechnology to target metastasis.
Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.
A new Canadian study suggests that individuals who take anti-depressants and/or anti-psychotics and participate in a weight management program can lose weight whether or not they take psychiatric medications, according to a report published online today in Obesity, the flagship journal of The Obesity Society.
Australian researchers have begun a world-first study that aims to help men lose weight and prevent diabetes - by giving them more testosterone.
GlaxoSmithKline has issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes.
› Verified 1 days ago
News Archive
A new treatment strategy using targeted nanoparticles to block metastasis with anti-cancer drugs leads to good results using significantly lower doses of toxic chemotherapy, with less collateral damage to surrounding tissue, according to a collaborative team of researchers at the Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer at the University of California, San Diego. In designing this system, the investigators, led by David Cheresh, Ph.D., have identified what may become a generic method for using nanotechnology to target metastasis.
Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.
A new Canadian study suggests that individuals who take anti-depressants and/or anti-psychotics and participate in a weight management program can lose weight whether or not they take psychiatric medications, according to a report published online today in Obesity, the flagship journal of The Obesity Society.
Australian researchers have begun a world-first study that aims to help men lose weight and prevent diabetes - by giving them more testosterone.
GlaxoSmithKline has issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes.
› Verified 1 days ago
Norman Jaeger Counseling Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 125 W Indiantown Rd Ste 106, Jupiter, FL 33458 Phone: 561-312-5256 | |
Family Counseling Associates Inc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 4425 Military Trail, Suite 203, Jupiter, FL 33458 Phone: 561-747-2775 Fax: 561-747-1881 | |
Sarah R Sacks Inc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 725 N Highway A1a Ste A104, Jupiter, FL 33477 Phone: 561-575-2020 | |
Brent Berman & Associates Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 900 S Us Highway 1, Suite 101, Jupiter, FL 33477 Phone: 201-621-2160 Fax: 772-221-0449 | |
Seaglass Psychiatry, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 345 Jupiter Lakes Blvd Ste 302b, Jupiter, FL 33458 Phone: 772-202-6878 Fax: 334-232-2473 | |
Bright Minds Aba Therapy Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 110 Front St Ste 341, Jupiter, FL 33477 Phone: 561-785-3839 | |
Centerforbrain Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 550 Heritage Dr, Suite 140, Jupiter, FL 33458 Phone: 561-744-7616 Fax: 866-624-6184 |